CRVS250117C14000
- 0.05
- 0.000.00%
Corvus Pharmaceuticals Newsroom
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Corvus Wins New Buy From H.C. Wainwright Despite Recent Selloff
H.C. Wainwright Initiates Corvus Pharmaceuticals(CRVS.US) With Buy Rating
This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Corvus Pharma Analyst Ratings
Citi Initiates Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $11
Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS) and Veru (VERU)
Express News | Corvus Pharmaceuticals, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $11
Here's Why We're Not At All Concerned With Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $14
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $12
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Corvus Falls After Early-stage Data for Eczema Therapy
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell
Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost
Express News | Corvus Pharmaceuticals Inc - Lowest Dose Level Cohorts Show Favorable Safety and Efficacy
Market-Moving News for December 18th